ATHE is Alterity Therapeutics Limited (Healthcare) — a non-dividend-paying stock. Trading at $4.52. Market cap: $82M.
Stock snapshot
| Price | $4.52 |
| Market cap | $82M |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About ATHE
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.
Frequently asked
What is ATHE's current stock price?
ATHE (Alterity Therapeutics Limited) is currently trading at $4.52.
Does ATHE pay a dividend?
ATHE (Alterity Therapeutics Limited) does not currently pay a regular dividend.
Track ATHE in DiviDrip
Add ATHE to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search ATHE and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-04. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.